{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'Figure 2', 'Crossover Extension Schema', 'Treatment: Days 1, 8 & 15 of', 'ARM B: Docetaxel,', 'COE: Enfortumab Vedotin', 'each 28-day cycle until', 'Follow-up for PFS2/OS', 'Paclitaxel or Vinflunine', 'discontinuation criteria met', 'COE: crossover extension; OS: overall survival; PFS2: progression free survival on subsequent therapy', '14 Sep 2020', 'Astellas', 'Page 121 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'Table 11', 'Schedule of Assessments for Crossover Extension', 'End of', 'Long Term PFS2', 'Survival', 'Visit', 'Every Cycle', 'Follow-up2', 'Treatment', 'Treatment\u00b9', 'Follow-up', 'Follow-up', 'Date of last', 'Every', 'Date of Last', 'Base Date', 'Day 1', 'Day 8', 'Day 15', 'Dose + 30', '56 Days', 'Dose', 'Every 3 months', 'Every 3 months', 'days', 'Visit Window', '3 days', '3 day', '3 days', '7 days', '+ 7 days', '+ 7 days', '7 days', '7 days', 'Informed Consent', 'X3,4', 'Confirmation of Eligibility', 'X3,4', 'for COE', 'Brain Scan5', 'X3,5', 'X5', 'Bone Scan6', 'X6', 'X6', 'Serum/Urine Pregnancy', 'X', 'X', 'X', 'X7', 'X7', 'Test7', 'Physical Examination8', 'X', 'X', 'Weight8', 'X', 'X', 'X', 'X', 'Vital Signs8', 'X', 'X', 'X', 'X', 'X', 'Biochemistry9', 'X', 'X', 'X', 'X', 'X', 'Hemoglobin A1C10', 'X', 'X', 'Hematology11', 'X', 'X', 'X', 'X', 'X', 'ECOG PS', 'X', 'X', 'X', '12-lead ECG12', 'X3,12', 'X12', 'Ophthalmology', 'X', 'X', 'Assessment13', 'COE Enrollment via IRT', 'X4', 'EV Administration', 'X', 'X', 'X', 'Image Assessment14', 'X', 'X14', 'Concomitant Medication', 'X', 'X', 'X', 'X', 'X', 'X', 'Adverse Events', 'X', 'X', 'X', 'X', 'X', 'X', 'QOL15', 'X', 'X', 'X', 'HRU16', 'X16', 'X', 'X', 'Table continued on next page', '14 Sep 2020', 'Astellas', 'Page 122 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'Long Term PFS2', 'End of', 'Survival', 'Visit', 'Every Cycle', 'Treatment', 'Follow-up2', 'Treatment', 'Follow-up', 'Follow-up', 'Date of last', 'Every', 'Date of Last', 'Base Date', 'Day 1', 'Day 8', 'Day 15', 'Dose + 30', 'Every 3 months', 'Every 3 months', '56 Days', 'Dose', 'days', 'Visit Window', '3 days', '3 day', 'I 3 days', '7 days', '+ 7 days', '+ 7 days', '7 days', '7 days', 'ATA 19', 'X', 'X', 'X', 'Subsequent Therapy', 'X', 'X', 'assessment17', 'Overall Survival18', 'X', 'X', 'X', 'AE: adverse event; ALT: alanine transaminase; AST: aspartate transaminase; ATA: antitherapeutic antibody; C: cycle; COE: crossover extension; CR: complete', 'response; CT: computed tomography; D: day; ECG: electrocardiogram; ECOG PS: Eastern Cooperative Oncology Group Performance Status; EORTC-QLQ-', 'C30: European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire; EOT: end of treatment; EQ-5D-5L: EuroQOL', '5-', 'Dimension 5-Level Questionnaire; EV: enfortumab vedotin; HRU: health resource utilization; MRI: magnetic resonance imaging; NA: Not Applicable; PD:', 'progressive disease; PFS1: progression free survival on study therapy; PFS2: progression free survival on subsequent therapy; PGx: Pharmacogenetic analyses;', 'PR: partial response; QOL: quality of life; RECIST: Response Evaluation Criteria in Solid Tumors', '1. EOT visit will occur within 7 days after the last dose or when the decision is made by the investigator to discontinue subject from treatment.', '2. Follow up assessments should be completed prior to the initiation of the next therapy.', '3. May be completed within 28 days prior to COE C1D1 visit.', '4.', 'COE Cycle 1 only.', '5. Only if clinically indicated at time of COE eligibility assessment. Repeat as clinically indicated or per standard of care throughout the study.', '6.', 'All subjects will have a bone scan (scintigraphy) within 28 days prior to COE C1D1 dosing. Subjects with positive bone scans at time of COE eligibility', 'assessment will have a bone scan performed every 56 days ( 7 days) throughout the study or more frequently if clinically indicated. Subjects should', 'have a follow-up bone scan performed if clinically indicated regardless of status at time of COE eligibility assessment.', '7. For all female subjects of child bearing potential only, a urine or serum pregnancy test will be performed within -7 days of COE C1D1 visit. A urine or', 'serum pregnancy test will be performed at COE Day 1 prior to dosing, on day 1 of each cycle prior to EV administration, at EOT and Follow-up visits.', 'After EOT, a monthly ( 7 days) pregnancy test will be maintained until 6 months after the last dose of study treatment.', '8. Full Physical examination, weight, ECOG PS and vital signs (pulse, temperature and blood pressure) will be performed at COE C1D1 prior to dosing.', 'The physical examination will also be performed on day 1 of each cycle and EOT visit. For subsequent and EOT visits, physical examinations maybe', 'more directed but should include examination of lungs, abdomen, skin and cardiovascular systems. Vital signs and weight will be completed on', 'days', '1,', '8', 'and 15 of each cycle and at EOT visit. Vital signs will also be performed at follow up visit.', 'Footnotes continued on next page', '14 Sep 2020', 'Astellas', 'Page 123 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}